Viking Global Investors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,820,462
| Closed | -$4.84M | – | 106 |
|
|
2024
Q1 | $4.84M | Hold |
1,820,462
| – | – | 0.02% | 83 |
|
|
2023
Q4 | $4.31M | Hold |
1,820,462
| – | – | 0.02% | 79 |
|
|
2023
Q3 | $2.55M | Hold |
1,820,462
| – | – | 0.01% | 80 |
|
|
2023
Q2 | $5.52M | Hold |
1,820,462
| – | – | 0.02% | 86 |
|
|
2023
Q1 | $11.4M | Hold |
1,820,462
| – | – | 0.05% | 76 |
|
|
2022
Q4 | $11.1M | Hold |
1,820,462
| – | – | 0.06% | 72 |
|
|
2022
Q3 | $21.8M | Hold |
1,820,462
| – | – | 0.1% | 78 |
|
|
2022
Q2 | $23M | Hold |
1,820,462
| – | – | 0.11% | 76 |
|
|
2022
Q1 | $20.5M | Hold |
1,820,462
| – | – | 0.08% | 85 |
|
|
2021
Q4 | $32.3M | Hold |
1,820,462
| – | – | 0.09% | 97 |
|
|
2021
Q3 | $41.9M | Hold |
1,820,462
| – | – | 0.11% | 85 |
|
|
2021
Q2 | $42.4M | Sell |
1,820,462
-51,561
| -3% | -$1.31M | 0.13% | 79 |
|
|
2021
Q1 | $58.3M | Hold |
1,872,023
| – | – | 0.17% | 79 |
|
|
2020
Q4 | $74.5M | Buy |
+1,872,023
| New | +$75.1M | 0.2% | 75 |
|
Viking Global Investors's KNTE Position: Q2 2024 in Review
Viking Global Investors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,820,462 shares — an estimated $4.84M sold.
Viking Global Investors first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $74.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Viking Global Investors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Viking Global Investors sold 1,820,462 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $4.84M.
- Viking Global Investors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Viking Global Investors's Kinnate Biopharma Inc. Common Stock position peaked at $74.5M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Viking Global Investors's 13F filing for Q2 2024, filed 14 Aug 2024.